Eloralintide for knee osteoarthritis pain in adults who are overweight or have obesity
Tests eloralintide against placebo in adults with painful knee osteoarthritis and excess weight.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Key facts
- Where
- Buenos Aires, Granadero Baigorria, Rosario, San Fernando, San Isidro, San Juan, SAN M. de Tucuman, San Miguel de Tucumán, and San Nicolás, ArgentinaSee the 14 sites
- Phase
- Phase 3
Where in Argentina
- CARDIAMET Investigaciones MédicasBuenos Aires, ArgentinaNot yet recruiting
- Centro Médico ArsemaBuenos Aires, ArgentinaNot yet recruiting
- Centro Privado de Medicina Familiar / Mindout ResearchBuenos Aires, ArgentinaNot yet recruiting
- Organización Médica de InvestigaciónBuenos Aires, ArgentinaNot yet recruiting
- Stat Research S.A.Buenos Aires, ArgentinaNot yet recruiting
- Centro de Investigaciones Clínicas BaigorriaGranadero Baigorria, ArgentinaNot yet recruiting
- INECO Neurociencias OroñoRosario, ArgentinaNot yet recruiting
- Instituto Especialidades de la Salud RosarioRosario, ArgentinaNot yet recruiting
- Medicina ReumatológicaSan Fernando, ArgentinaNot yet recruiting
- Instituto de Alta Complejidad San IsidroSan Isidro, ArgentinaNot yet recruiting
- Centro Polivalente de Asistencia E Investigacion Clinica Cer San JuanSan Juan, ArgentinaNot yet recruiting
- Centro de Investigaciones Médicas TucumanSAN M. de Tucuman, ArgentinaNot yet recruiting
- Centro de Investigaciones ReumatológicasSan Miguel de Tucumán, ArgentinaNot yet recruiting
- Go Centro Medico San NicolásSan Nicolás, ArgentinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07353931EU 2025-523768-19-00
- Record updated
- 4 November 2026
- Original description
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.Read full original descriptionShow less
A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4)
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.
Inclusion: Have a body mass index (BMI) of 27 kilograms per square meter (kg/m²) or higher at screening; Have a stable body weight (less than 5% body weight change) for 90 days prior to screening; Have tried at least once to lose weight through diet but were unsuccessful; Have osteoarthritis of the knee and at least one of the following conditions:; Be over 50 years old; Have morning knee stiffness that lasts about 30 minutes; Have a crackling or grinding sound or feeling in the knee.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed greater than 1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have taken medications or alternative remedies intended for weight loss within 90 days of screening; Have type 1 diabetes, type 2 diabetes, or any other type of diabetes; Have an active knee infection; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure.